<DOC>
	<DOCNO>NCT01364298</DOCNO>
	<brief_summary>This multicenter , randomize , open-label , parallel , Phase 4 clinical trial compare efficacy safety gabapentin/B-complex versus pregabalin diabetic peripheral neuropathy pain ( DPNP ) management .</brief_summary>
	<brief_title>Efficacy Safety Gabapentin/B-complex Versus Pregabalin Diabetic Peripheral Neuropathy Pain Management</brief_title>
	<detailed_description>Primary Objective : To compare efficacy gabapentin/B-complex versus pregabalin administer 12 week treatment pain mild moderate diabetic peripheral neuropathy ( DPN ) acute chronic presentation . Secondary Objectives : To determine safety tolerability gabapentin/B-complex versus pregabalin administer 12 week treatment pain mild moderate DPN acute chronic presentation . Subjects randomize 1:1 ratio receive gabapentin/B-complex pregabalin . The duration treatment per subject 12 week .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Females male undististincally Age 18 70 year Signed informed consent ( IC ) subject Diabetes mellitus ( DM ) Type 1 2 Pain due sensorial motor DPN low moderate intensity , great equal ( &gt; = ) 1 year evolution less equal ( = &lt; ) 5 year diagnosed Subjects score &gt; =40 millimeter ( mm ) visual analogue scale ( VAS ) McGill pain questionnaire ( MPQ ) selection Baseline visit , complete daily basis numeric pain intensity ( NPI ) ( least 4 day week ) week previous randomization whose daily mean score least 4 , 7 day previous randomization ( washout period ) Normal chest radiography Stable hypoglycemic treatment , least 6 week randomization Glycosylated hemoglobin ( HbA1c ) = &lt; 10 percent selection visit Women must pregnant must pregnancy plan period study duration Subjects medicate analgesic stable medication minimum 4 week , acceptable relief pain achieve ; last case , correspond washout period Women childbearing age must submit negative pregnancy test treatment randomization use contraceptive method medically accept , study period Suicide risk define score 2 high , question 9 beck depression test Congestive heart failure Class III IV New York Heart Association ( NYHA ) Subjects serious unstable coronary heart disease , hepatic , kidney , respiratory , hematological alteration , problem peripheral vascular disease , medical psychiatric condition put risk participation subject study may lead hospitalization study period Any condition may lead confusion diagnostic painful DPN , particular amputation fingers/toes , diabetic neurological disorder skin condition may affect sensation painful limbs Subjects Baseline calculate creatinine clearance less ( &lt; ) 60 milliliter per minute ( mL/min ) , Baseline leukocyte count &lt; 2,500 per cubic millimeter ( /mm^3 ) , Baseline neutrophils count &lt; 1,500/mm^3 platelet &lt; 100 * 10^3 /mm^3 Subjects participate previously study pregabalin gabapentin gabapentin/Bcomplex , 30 day previous selection Subjects encephalopathy cause ammonia alteration cycle urea Subjects uncontrolled closedangle glaucoma Subject presence disorder anticonvulsant treatment Breastfeeding woman first 3 month postpartum Morbid obesity ( body mass index [ BMI ] &gt; =40 ) Glycosylated hemoglobin ( HbA1c ) great ( &gt; ) 10 percent Major surgery 3 month previous randomization Any surgery 2 week previous randomization process , program study period authorize Sponsor appoint representative Blood donor 60 day previous randomization Abuse dependency alcohol , narcotic , opioids addictive substance , energize drink History hypersensitivity drug study drug similar chemical structure History suspicion lack trust , poor cooperation lack compliance medical treatment Subjects arthritis , sciatic , fibromyalgia , restless leg syndrome , nonneuropathic muscleskeletal pain back chronic pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Gabapentin/B complex</keyword>
	<keyword>Pregabalin</keyword>
	<keyword>Pain</keyword>
	<keyword>Neuropathic</keyword>
	<keyword>Gavindo</keyword>
	<keyword>Lyrica</keyword>
</DOC>